Intelligence Feed event · Equity · 2026-10-08

    Bavarian Nordic Raises 2026 Travel Health Revenue Guidance to DKK 3.4B

    Question

    Bavarian Nordic Raises 2026 Travel Health Revenue Guidance to DKK 3.4B

    Direct answer

    Bavarian Nordic lifted its 2026 financial outlook, increasing expected Travel Health division revenue from DKK 3,000 million to DKK 3,400 million. The upward adjustment is credited to accelerated U.S. demand for rabies vaccines connected to heightened regional wildlife rabies occurrences.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-08
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bavarian Nordic Raises 2026 Travel Health Revenue Guidance to DKK 3.4B”, revision 1, evidence through 2026-10-08. https://marketontology.com/market-events/2026-10-08/bavarian-nordic-raises-2026-travel-health-revenue-guidance-to-dkk-3-4b-ad70bf

    EQUITY
    Bavarian Nordic Raises 2026 Travel Health Revenue Guidance to DKK 3.4B
    Bavarian Nordic lifted its 2026 financial outlook, increasing expected Travel Health division revenue from DKK 3,000 million to DKK 3,400 million. The upward adjustment is credited to accelerated U.S. demand for rabies vaccines connected to heightened regional wildlife rabies occurrences.
    BVNRY
    Impact
    68
    OCT 8
    SIG
    90%
    BVNRY
    Bavarian Nordic Raises 2026 Travel Health Revenue Guidance to DKK 3.4B
    Bavarian Nordic lifted its 2026 financial outlook, increasing expected Travel Health division revenue from DKK 3,000 million to DKK 3,400 million. The upward adjustment is credited to accelerated U.S. demand for rabies vaccines connected to heightened regional wildlife rabies occurrences.
    → Direct segment guidance upgrades lift forward operating earnings projections and free cash flow generation for BVNRY ADRs.
    Impact
    Bavarian Nordic lifted its 2026 financial outlook, increasing expected Travel Health division revenue from DKK 3,000 million to DKK 3,400 million. The upward adjustment is credited to accelerated U.S. demand for rabies vaccines connected to heightened regional wildlife rabies occurrences.
    Affected
    BVNRY
    Transmission
    Direct segment guidance upgrades lift forward operating earnings projections and free cash flow generation for BVNRY ADRs.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BVNRYguidance upgrade lifting 2026 operating cash flow and revenue consensusUp1-5dTravel Health revenue guidance raised to DKK 3,400M from DKK 3,000M.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    BVNRYUpagreed11.48 2026-10-08+2.61%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month